Abstract:Ischemic stroke is one of the leading causes of adult disability and cognitive impairment worldwide. Thrombolysis has been a standard treatment for ischemic stroke. However, due to the short time-window for thrombolytic agent administration, most patients cannot benefit from rt-PA treatment by missing this therapeutic time-window. Neuroprotection aims to improve the survival of brain tissues by impeding the devastating ischemic cascade events. Even though the neuroprotectant can be applied in the acute, subacute, and chronic stages of ischemic stroke, their therapeutic efficiencies are compromised by the blood-brain barrier (BBB) that restricts brain drug uptake. Therefore, specifically increasing neuroprotectant delivery in brain ischemia will improve the treatment efficiency. In this chapter, we first introduce the dynamics of structure, permeability, and transcytosis of BBB after the onset of ischemic stroke. Temporarily increasing para-endothelial diffusion, taking advantage of the up-regulated intra-endothelial transcytosis, and attenuating the pro-inflammatory response are summarized as the key issues to increase drug delivery efficiency in the acute, subacute, and chronic stages, respectively. Finally, recent reported strategies facilitating brain delivery of neuroprotectants by overcoming the BBB via intra-endothelial transcytosis or para-endothelial diffusion are introduced. Overall, elucidating BBB dynamics after ischemic attack helps to design new drug delivery vectors to maximize neuroprotective response, but minimize the potential side effects induced by the vascular leakage. Up-regulating neuroprotectant uptake in brain ischemia will benefit majority of ischemic stroke patients who lost the chance for thrombolytic treatment.

Savaging Brain Ischemia by Increasing Brain Uptake of Neuroprotectants